Abstract
Hypoxia in head and neck tumors has proven to be predictive of outcomes. Current hypoxia signatures have failed for patient treatment selection. In a recent study, the authors identified a hypoxia methylation signature as a more robust biomarker in head and neck squamous cell carcinoma and shed light into the mechanism of hypoxia-mediated treatment resistance. See related article by Tawk et al., p. 3051.
©2023 American Association for Cancer Research.
Publication types
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Carcinoma, Squamous Cell* / genetics
-
Carcinoma, Squamous Cell* / pathology
-
Carcinoma, Squamous Cell* / radiotherapy
-
Chemoradiotherapy
-
DNA
-
Epigenome
-
Head and Neck Neoplasms* / genetics
-
Head and Neck Neoplasms* / radiotherapy
-
Humans
-
Hypoxia / genetics
-
Neoplasm Recurrence, Local
-
Papillomavirus Infections*
-
Prognosis
-
Squamous Cell Carcinoma of Head and Neck / genetics
-
Squamous Cell Carcinoma of Head and Neck / radiotherapy
-
Tumor Hypoxia / genetics